FLEXTRADE-SYSTEMS
9.9.2021 09:02:03 CEST | Business Wire | Press release
Appital, the Equity Capital Marketplace, today announced that FlexTrade Systems (@FlexTrade ), a global leader in multi-asset execution and order management systems, is the first EMS provider to integrate with Appital’s bookbuilding platform.
By working with pioneering firms like FlexTrade, Appital is driving the technological infrastructure development necessary to integrate their platform into existing market structures and bring innovation and automation to equity capital markets.
Appital’s platform will be fully integrated with FlexTrade’s FlexTRADER EMS, bringing a historically manual order flow process to an automated platform. Through FlexTrade’s integration with Appital, buy-side firms will have access to the liquidity and efficiency of executing on Turquoise, LSEG’s (London Stock Exchange Group) pan-European MTF with seamless straight-through-processing (STP) to over 20 settlement venues. Sparked by demand from some of the largest asset management firms globally, the integration will offer the buy-side community a more efficient and transparent way to execute large orders with minimal market impact or risk of price erosion.
Andy Mahoney, Managing Director EMEA FlexTrade Systems, commented: “This integration with Appital brings transparency and automation to an area of the market traditionally plagued by opacity and outdated, phone based bookbuilding activity. We see significant demand for Appital’s offering from some of our largest asset management customers. As a result, we have been collaborating with Appital to develop standard integration procedures to ensure our clients have seamless access to Appital’s platform directly within the FlexTRADER EMS order blotter to actively participate in the liquidity discovery process in the market for size.”
The integration with FlexTrade has led to the establishment of a working group that includes some of the largest asset managers globally. The group helps mutual clients define how they want to interact with the hard-to-find liquidity in the market and proactively build books of demand, while ensuring that the integration to existing workflows remains seamless. Other EMS providers are now able to code to the established, FIX based protocols, to the benefit of the buy-side community overall.
Dr Robert Barnes, CEO, Turquoise Global Holdings & Group Head of Securities Trading at London Stock Exchange Group, said: “Turquoise is pleased to build on our innovation in partnership with Appital to unlock latent liquidity for the market. Through FlexTrade’s integration, buy-side participants can look forward to Appital’s novel bookbuilding and seamless execution to settlement of liquidity at the right price through Turquoise.”
Mark Badyra, CEO of Appital, said : “In our mission to put buy-side firms in control of their bookbuilding activity we are excited to work with innovative firms like FlexTrade to help us shape the technology infrastructure for EMS integrations. FlexTrade clients and the asset management community can now gain exposure to deal flow opportunities they have not been able to access before. This integration transforms a traditionally manual order flow process, that historically sits outside any EMS, into an automated, electronic platform.
Badyra added: “FlexTrade has been instrumental in developing the Appital workflow alongside ourselves and the team at Turquoise. This is a major step forward for not only our combined client base, but the market as a whole, and we look forward to scaling this integration market-wide in the coming months.”
Appital gives the buy-side community greater exposure to deal flow opportunities they have not been able to access before. Buy-side traders looking to execute large orders in excess of 5 days ADV, including in highly illiquid, small and mid-cap stocks, have access to real-time visibility, full transparency and maximum control over the bookbuilding and deal distribution process. They can proactively source liquidity and efficiently drive the bookbuilding process in real-time, on one automated platform, with the ability to make distribution adjustments throughout. What’s more, Appital users will be able to execute all deals through the Turquoise MTF, via a single point of access and with seamless straight-through-processing (STP) to over 20 settlement venues.
About Appital
Appital, the Equity Capital Marketplace, brings technological innovation and automation to equity capital markets, unlocking and uncovering liquidity for investors. The Appital platform allows the buy-side community to gain greater exposure to deal flow and execution opportunities in highly illiquid small and mid-cap stocks, often in excess of 5 days of ADV, with minimal market impact or risk of price erosion.
Appital’s distribution methodology is highly efficient, unbiased and unconflicted, delivering a fair outcome for all market participants. Appital’s buy-side community has access to real-time visibility, full transparency and maximum control over the bookbuilding and deal distribution process.
The Appital platform can be integrated into existing OMS and EMS systems and workflows, and the desktop application is also available on OpenFin. For more information please visit our website and follow us on Twitter @AppitalHQ and LinkedIn .
About FlexTrade :
FlexTrade Systems is a global leader in high performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER®, the world’s first broker-neutral, execution management trading system, which allows clients to completely control and customize their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
